GLIMEPIRIDE 2mg. IP + METFORMIN 1000mg. IP

An antihyperglycemic drug that prevents blood glucose levels from rising to very high levels. Increases the amount of insulin released by the pancreas to lower blood glucose. (Maria L.A.D. Lestari, 2011) Effectively reduces fasting plasma glucose, postprandial glucose, and glycosylated hemoglobin levels. (Abdul Basit, 2012) A valuable, cost-effective treatment option for managing type 2 diabetes mellitus. (Abdul Basit, 2012) Shows high efficacy over conventional sulfonylureas and lower risk of hypoglycemia with neutral cardiovascular risk. (Rakesh Kumar Sahay V. M., 2020) A promising drug in the management of type 2 diabetes patients with comorbidities like hypertension, dyslipidemia, and diabetes complications. (Rakesh Kumar Sahay V. M., 2020) A safe, cost-effective, and effective approach for the management of type 2 diabetes mellitus. (Rakesh Kumar Sahay, 2020) The preferred choice for the management of diabetes across all age groups. Exhibits more potent glucose-lowering effects than glyburide. (Fahir Becić, 2003) Offers a lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. (Abdul Basit, 2012) An alternative to other sulphonylureas in type 2 diabetes mellitus subjects not well controlled by diet alone. (H D Langtry, 1998) Shows superior efficacy than metformin or glimepiride monotherapy in type 2 diabetes patients who had failed glucose control with metformin. (Hye-soon Kim, 2014)